ANXA5 and cancer: Lastly, Anxa5 expression is upregulated early in the progression to hepatocellular carcinoma [56] and here we demonstrate that t-TUCB-FLVs decreased its expression, suggesting potential anti-cancer activities of s-EH inhibition.